Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a Mendelian randomization study

Key Points

• FCGR3B shows a causal effect on Alzheimer's disease risk, linking it to potential therapies.
• The analysis identified FCGR3B as a significant target, while others were not shown to influence risk.
• Mendelian randomization was employed to assess the relationship between DMARD targets and Alzheimer's disease.
• Further research is necessary to understand FCGR3B's role and validate its therapeutic potential.